Key result
TAPSE/sPAP ≤0.20 and NYHA III-IV predict ~301% higher mortality in medically treated CTEPH.
Why the study?
The prognostic importance of the TAPSE/sPAP ratio in medically treated chronic thromboembolic pulmonary hypertension (CTEPH) patients is limited and requires clarification.
Does a lower TAPSE/sPAP ratio predict mortality in medically treated CTEPH patients?
Cohort (n=56)
No
Does a lower TAPSE/sPAP ratio predict mortality in medically treated CTEPH patients?
A TAPSE/sPAP ratio ≤0.20 combined with NYHA functional class III-IV is an independent predictor of poor prognosis and mortality in medically treated CTEPH patients.
Answers are grounded in this paper and cite their sources.
May aid prognostication in medically treated CTEPH; leaves open prospective validation before guiding therapy.
Objective: The ventriculoarterial uncoupling has been linked with unfavorable results as measured noninvasively by tricuspid annular plane systolic excursion divided by systolic pulmonary artery pressure (TAPSE/sPAP).However, its prognostic importance in chronic thromboembolic pulmonary hypertension (CTEPH) is limited.Thus, we determine the effect of the TAPSE/sPAP ratio on outcomes and predictors of all-cause mortality in these patients. Methods:We analyzed 56 subjects with medically treated CTEPH.Two-dimensional echocardiographic examination and right heart catheterization findings were recorded from the hospital database.Baseline New York Heart Association functional class (NYHA-FC), 6-min walk distance (6MWD), and brain natriuretic peptide (BNP) test results were recorded.Results: The median age was 65.5 years.Over a median follow-up time of 27 months, 29 (51.8%)patients died.BNP values were higher (P = 0.008), 6MWD values were lower (P = 0.004), and NHYA-FC (P = 0.0001) was worse in the non-survivor group.TAPSE (P = 0.0001) and TAPSE/sPAP ratio (P = 0.001) were significantly lower and pulmonary vascular resistance (PVR) was higher in the non-survivor group (P = 0.03).The best cut-off value for the TAPSE/ sPAP ratio for predicting mortality was 0.20 mm/mmHg and the survival rates were significantly lower in the TAPSE/sPAP ratio ≤0.20 group (log-rank P = 0.012).6MWD (P = 0.005), NHYA-FC III-IV (P = 0.0001), TAPSE/sPAP ratio ≤0.20 (P = 0.017), PVR (P = 0.008), and TAPSE/sPAP ratio ≤0.20 combined with NYHA-FC III-IV (P = 0.0001) were significant determinants and TAPSE/sPAP ratio ≤0.20 combined with NYHA-FC III-IV was the only independent predictor of mortality (P = 0.003).Conclusion: Medically treated CTEPH patients with a TAPSE/sPAP ratio ≤0.20 had lower survival rates.TAPSE/sPAP ratio≤0.20 combined with NYHA-FC III-IV was the independent predictor of poor prognosis.Keywords: Chronic thromboembolic pulmonary hypertension, mortality, tricuspid annular plane systolic excursion divided by systolic pulmonary artery pressure ratio ÖZET Amaç: Ventriküloarteriyel ayrılmayı gösteren, noninvaziv olarak ölçülen triküspid anüler düzlem sistolik hareketinin sistolik pulmoner arter basıncına bölünmesi ile elde edilen TAPSE/sPAP oranının olumsuz sonuçlarla ilişkili olduğu gösterilmiştir.Ancak TAPSE/sPAP oranının kronik tromboembolik pulmoner hipertansiyon (KTEPH) hastalarındaki prognostik değeri sınırlıdır.Bu çalışmada KTEPH hastalarında TAPSE/sPAP oranının prognoz üzerine etkisi ve bu hastalarda mortalite prediktörlerinin belirlenmesi amaçlanmıştır.Yöntem: Medikal olarak tedavi edilen 56 KTEPH olgusu analiz edildi.İki boyutlu ekokardiyografik inceleme ve sağ kalp kateterizasyon bulguları hastane veritabanından kaydedildi.New York Kalp Derneği fonksiyonel sınıfı (NYHA-FS), 6 dakika yürüme mesafesi (6DYM) ve beyin natriüretik peptid (BNP) testi sonuçları kaydedildi.Bulgular: Olguların medyan yaşı 65,5 yıldı.Medyan 27 aylık takip süresi boyunca 29 (%51.8)hastada mortalite gözlendi.Hayatta olmayan grupta BNP değerleri anlamlı olarak daha yüksek (P = 0.008), 6DYM değerleri daha düşüktü (P = 0.004) ve NHYA-FS değerleri daha kötüydü (P = 0.0001).TAPSE (P = 0.0001) ve TAPSE/sPAP oranı (P = 0.001) hayatta olmayan grupta anlamlı olarak daha düşük ve pulmoner vasküler direnç (PVR) anlamlı olarak daha yüksekti (P = 0.03).Mortaliteyi öngörmek için TAPSE/sPAP oranı için en iyi kesme değeri 0.20 mm/mmHg idi ve sağkalım oranları TAPSE/sPAP oranı ≤0.20 grubunda anlamlı olarak daha düşüktü (log-rank P = 0.012).Mortalite belirleyicileri 6DYM (P = 0.005), NHYA-FS III-IV (P = 0.0001), TAPSE/
No takes yet. Share an insight, caveat, or question.
Ayşe Çolak (2023) conducted a cohort in Chronic thromboembolic pulmonary hypertension (CTEPH) (n=56). TAPSE/sPAP ratio ≤0.20 combined with NYHA-FC III-IV vs. TAPSE/sPAP ratio >0.20 and/or NYHA-FC I-II was evaluated on All-cause mortality (HR 4.008, 95% CI 1.588-10.115, p=0.003). In medically treated patients with chronic thromboembolic pulmonary hypertension, a TAPSE/sPAP ratio ≤0.20 combined with NYHA-FC III-IV independently predicted all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: